We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Acquires Caelum Biosciences, Pushing Further Into Rare Diseases
AstraZeneca Acquires Caelum Biosciences, Pushing Further Into Rare Diseases
AstraZeneca’s rare-diseases subsidiary Alexion has announced that it will acquire Caelum Biosciences, which nets the company a potentially first-in-class monoclonal antibody for the treatment of the rare disease light-chain (AL) amyloidosis.